Panacea Biotec Ltd (PANACEABIO)
₹379.00
Mkt cap
₹2,335 Cr
P/E ratio
—
P/B
2.79
Div yield
0.00%
ROE
−2.36%
ROCE
−2.44%
EPS (TTM)
—
Book value
₹136
52W range
296–608
Sector
Healthcare
Price history
Previous close
Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company [1]
NSE PANACEABIOBSE 531349
Health check
Cautious
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−37.64% from high₹379
₹296+28.02% from low₹608
Current
₹379.00
Prev close
₹380.10
Day
−0.29%
Price performance
1D
−0.29%
1W
−2.09%
1M
−8.23%
3M
−37.64%
6M
+18.29%
1Y
−8.93%
YTD
−0.22%
Financials
Revenue, profit & margin
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 129.19 | 143.02 | 150.50 | 136.46 | 115.72 | 147.35 | 163.49 | 132.53 | 166.70 | 141.13 | 165.19 | 166.75 | 199.57 | |
| Expenses | 139.50 | 146.58 | 150.65 | 142.50 | 129.71 | 140.35 | 155.53 | 159.41 | 167.88 | 158.92 | 153.45 | 164.18 | 193.90 | |
| Operating Profit | -10.31 | -3.56 | -0.15 | -6.04 | -13.99 | 7.00 | 7.96 | -26.88 | -1.18 | -17.79 | 11.74 | 2.57 | 5.67 | |
| OPM % | -7.98% | -2.49% | -0.10% | -4.43% | -12.09% | 4.75% | 4.87% | -20.28% | -0.71% | -12.61% | 7.11% | 1.54% | 2.84% | |
| Other Income | 33.82 | 6.00 | 8.46 | 13.55 | 6.54 | 7.42 | 6.39 | 36.30 | 16.99 | 9.10 | 5.05 | 5.26 | 6.98 | |
| Interest | 1.00 | 0.91 | 0.85 | 0.82 | 0.87 | 0.98 | 0.99 | 1.04 | 0.86 | 2.14 | 1.85 | 1.20 | 1.18 | |
| Depreciation | 9.48 | 9.31 | 9.11 | 8.81 | 8.73 | 8.68 | 8.98 | 8.42 | 8.39 | 8.34 | 8.45 | 7.88 | 7.90 | |
| Profit before tax | 13.03 | -7.78 | -1.65 | -2.12 | -17.05 | 4.76 | 4.38 | -0.04 | 6.56 | -19.17 | 6.49 | -1.25 | 3.57 | |
| Tax % | 15.73% | 6.56% | 33.33% | -6.13% | -6.86% | 1.05% | -1.37% | 4,875.00% | 39.63% | -26.92% | 40.06% | -20.00% | 38.38% | |
| Net Profit | 10.98 | -8.29 | -2.20 | -1.99 | -15.88 | 4.71 | 4.44 | -1.99 | 3.96 | -14.01 | 3.89 | -1.00 | 2.20 | |
| EPS in Rs | 1.79 | -1.35 | -0.37 | -0.32 | -2.58 | 0.78 | 0.74 | -0.31 | 0.66 | -2.27 | 0.65 | 0.08 | 0.38 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202672.48%Promoter
Promoters72.48%
FIIs2.31%0.71
DIIs2.25%0.29
Public22.96%1.00
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| PANACEABIO | ₹381.25 | — | 2,335 | 0.00% | 2 | +113.06% | 200 | +19.72% | −2.44% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013nseAnnual Report 2013bseAnnual Report 2012nse
Concall transcripts2
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 18 Aug - Newspaper copies of the public notice, requesting shareholders to register their email addresses with the Company in connection with ensuing AGM of the Company.Announcement under Regulation 30 (LODR)-Newspaper Publication 14 Aug - Please find attached of the extract of statement of Unaudited Financial Results for the quarter ended 30.06.2026, published on 14.08.2026.Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter Ended June 30, 2026 13 AugBoard Meeting Outcome for Outcome Of Board Meeting Held On August 13, 2026 13 Aug - Q1 FY27 results: standalone profit ₹139 lakh, consolidated profit ₹220 lakh; AGM on Sep 29, 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 12 Aug - Please find attached newspaper copies regarding notice intimating the investors about the opening of Special Window for transfer and dematerialisation of physical shares.